[Clinical evaluation of sulbactam/ampicillin in children].
[Clinical evaluation of sulbactam/ampicillin in children].
复制标题
舒巴坦/氨苄西林在儿童中的临床评价
DOI：
--
复制
发表时间：
1989
期刊：
影响因子：
--
通讯作者：
H. Mikawa
中科院分区：
文献类型：
--
作者：
S. Ito;M. Mayumi;M. Ito;H. Mikawa
舒巴坦/氨苄西林（SBT/ABPC）是一种不可逆的β -内酰胺酶抑制剂，ABPC与SBT按固定比例以2:1的比例联合使用。我们对24例5月龄至12岁的细菌感染患者进行了临床疗效和安全性评价。所得结果总结如下：1. 经30 mg/kg SBT/ABPC滴注或静脉滴注30 min后的药代动力学研究表明，SBT和ABPC的平均半衰期分别为48.9 min和40.2 min，前6 h SBT和ABPC的平均尿排泄率分别为67.1%和48.3%。2. SBT/ABPC治疗支气管肺炎14例，扁桃体炎4例，急性上呼吸道感染、下颌下淋巴结炎、痰、小肠结肠炎、肾盂肾炎、膀胱炎各1例，每日剂量88.2 ~ 133.3 mg/kg，分3组或4组，静脉滴注或点滴滴注30 min。24例患者临床反应：优17例，良7例。有效率100%。3. 除了患者轻度嗜酸性粒细胞增多和另一人GOT、GPT升高外，未观察到临床不良反应和异常实验室检测值。4. SBT/ABPC对部分患者分离的7株强β -内酰胺酶产菌的mic如下：对1株金黄色葡萄球菌的MIC为3.13微克/ml，对2株卡他氏布兰默氏菌的MIC为0.10微克/ml，其余3株的MIC为0.20微克/ml。对副流感嗜血杆菌的MIC为3.13微克/毫升。5. 上述数据表明，SBT/ABPC对产生β -内酰胺酶的细菌以及不产生β -内酰胺酶的革兰氏阳性菌和阴性菌具有优异的杀菌能力，提示SBT/ABPC是一种非常有用的儿科抗生素。
Sulbactam/Ampicillin (SBT/ABPC), a combination at a fixed ratio of ABPC and SBT which is an irreversible inhibitor of beta-lactamase in a 2:1 ratio, was clinically evaluated for its efficacy and safety in 24 patients with ages from 5 month-old to 12 years old with bacterial infection. The results obtained are summarized as follows. 1. A pharmacokinetic study following 30 mg/kg SBT/ABPC administration by 30 minutes drip infusion or intravenous bolus injection showed that mean half-lives of SBT and ABPC were 48.9 minutes and 40.2 minutes, respectively, and mean urinary excretion rates of SBT and ABPC in the first 6 hours were 67.1% and 48.3%, respectively. 2. SBT/ABPC was administered to 14 patients with bronchopneumonia, 4 patients with tonsillitis, a patient each with acute upper respiratory infection, with submandibular lymphadenitis, with phlegmon, with enterocolitis, with pyelonephritis and with cystitis at a daily dosage of 88.2-133.3 mg/kg, divided into 3 or 4, by intravenous bolus injection or by 30 minutes drip infusion. Clinical responses of the 24 patients were as follows: excellent: 17 patients, good: 7 patients. The efficacy rate was 100%. 3. Neither clinical adverse reactions nor abnormal laboratory test values, except slight eosinophilia in a patient and an elevation of GOT, GPT in another were observed. 4. MICs of SBT/ABPC against 7 strong beta-lactamase producing strains isolated from some of the patients were as follows. MIC against a strain of Staphylococcus aureus was 3.13 micrograms/ml, MICs against 2 out of 5 strains of Branhamella catarrhalis were 0.10 microgram/ml and those of the remaining 3 strains were 0.20 microgram/ml. MIC against a strain of Haemophilus parainfluenzae was 3.13 micrograms/ml. 5. These data described above show that SBT/ABPC has excellent bactericidal capacity against beta-lactamase producing bacteria as well as beta-lactamase non-producing Gram-positive and negative bacteria and suggest that SBT/ABPC is a very useful antibiotic for pediatric patients.